Precision BioSciences reports ~$121M cash, gets first CTA approval for PBGENE-HBV in Moldova

PRECISION BIOSCIENCES INC

Expected cash, cash equivalents, and restricted cash of ~$121M as of Sept 30, 2024 (preliminary, unaudited).
Received CTA approval in Moldova for PBGENE-HBV, a first-in-human in vivo gene editing study for chronic hepatitis B.
PBGENE-HBV targets and eliminates cccDNA and inactivates integrated HBV DNA, aiming for functional cure.
Company to host investor event on Nov 15, 2024 prior to AASLD meeting to share preclinical safety package and Phase 1 trial details.
Additional global CTA and IND submissions underway to accelerate patient enrollment across multiple sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.